| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | 0.1 | 0.6 |
| mRNA | S-Trityl-L-cysteine | FIMM | pan-cancer | AAC | -0.1 | 0.6 |
| mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | 0.018 | 0.6 |
| mRNA | ifosfamide | CTRPv2 | pan-cancer | AAC | 0.03 | 0.6 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.027 | 0.6 |
| mRNA | CIL70 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.6 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.021 | 0.6 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | -0.021 | 0.6 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.02 | 0.6 |